These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 18337642

  • 1. The similarities of aromatase inhibitors outweigh the differences.
    Jänicke F.
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S7-9. PubMed ID: 18337642
    [Abstract] [Full Text] [Related]

  • 2. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
    Singh Ranger G.
    J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
    Biganzoli L, Licitra S, Claudino W, Pestrin M, Leo AD.
    Eur J Cancer; 2007 Oct; 43(15):2270-8. PubMed ID: 17698345
    [Abstract] [Full Text] [Related]

  • 5. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT.
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
    [Abstract] [Full Text] [Related]

  • 6. Advances in adjuvant hormonal therapy for postmenopausal women.
    Strasser-Weippl K, Goss PE.
    J Clin Oncol; 2005 Mar 10; 23(8):1751-9. PubMed ID: 15755983
    [No Abstract] [Full Text] [Related]

  • 7. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC.
    Cancer Invest; 2008 Jun 10; 26(5):481-90. PubMed ID: 18568770
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The evolution of adjuvant endocrine therapy: developments since St Gallen 2005.
    Smith IE, Arnedos M.
    Breast; 2007 Dec 10; 16 Suppl 2():S4-9. PubMed ID: 17764939
    [Abstract] [Full Text] [Related]

  • 12. A practical overview of aromatase inhibitors.
    Younus J, Vandenberg TA.
    Anticancer Res; 2005 Dec 10; 25(3c):2497-502. PubMed ID: 16080483
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
    Del Mastro L, Clavarezza M, Venturini M.
    Cancer Treat Rev; 2007 Dec 10; 33(8):681-7. PubMed ID: 17850976
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
    Winer E.
    Clin Adv Hematol Oncol; 2008 Aug 10; 6(8):573-4. PubMed ID: 18820598
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.